Head-to-head evidence
ION337 vs STK-001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: SCN1A mRNA · full Epilepsy pipeline
ION337
Developed by Ionis Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2030 · NCT07531745 (registry estimate)
STK-001
Developed by Stoke Therapeutics, Inc.
NCT04442295 · Phase 1/2 · completed
The study was non-randomized, open-label, sequential, and had no comparator arm, with 62 participants. Its primary outcomes were safety, pharmacokinetic, and cerebrospinal-fluid exposure measures, and no primary-endpoint results are available.
Next expected readout: March 2029 · NCT04740476 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ION337's landscape · STK-001's landscape